In mantle cell lymphoma (MCL), research on PRMT5 inhibition showed that activating pro-apoptotic BCL-2 family genes such as BAX enhances cell sensitivity to venetoclax. This evidence concerns the gene BCL2 and mantle cell lymphoma.